secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001628280-23-029193
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics Q2 net loss $10.1M; VYN201 phase 1b data due Q3 2023
----------------------------------------------------------------------

- Net loss of $10.1M ($3.09 per share) vs $8.5M ($2.63) in Q2 2022; revenue flat at $0.1M.
- Cash and restricted cash $20.7M as of June 30, 2023; expects to fund operations through end of 2023.
- R&D expenses rose to $7.2M from $4.1M YoY, primarily due to VYN202 license payment and development costs.
- VYN201 Phase 1b preliminary safety/efficacy data in nonsegmental vitiligo anticipated in Q3 2023.
- VYN202 IND submission expected by year-end; Phase 1 trial to begin Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/0001628280-23-029193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828023029193/mnlo-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-029193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer